Patent Defense · Challenge Strategy
Patent Invalidity
Patents are presumed valid — but they can be challenged and invalidated. Six legal grounds, three venues, and very different costs and timelines. Here is how patent invalidity works.
The legal framework
Presumed valid — until proven otherwise
Every issued US patent carries a statutory presumption of validity under 35 U.S.C. § 282. This means that in any proceeding — whether litigation, licensing negotiation, or IPR — the party asserting invalidity bears the burden of overcoming that presumption.
In district court, the burden is clear and convincing evidence— a demanding standard. At the Patent Trial and Appeal Board (PTAB) in IPR, it drops to preponderance of evidence (more likely than not). This asymmetry is a primary reason defendants challenge patents at the PTAB before or concurrent with litigation.
District Court
Clear and convincing evidence
Higher bar — presumption of validity is strong
PTAB (IPR / PGR)
Preponderance of evidence
More likely than not — significantly easier
Invalidity grounds
Six ways to invalidate a patent
US patent law recognizes multiple grounds for invalidity. Most are statutory (codified in the patent statutes); inequitable conduct is judicially created. Each requires different evidence and strategy.
Ground 01
Anticipation
§ 102
Strong
A single prior art reference discloses every element of the claimed invention. Every claim element must be found in one document — not spread across multiple references. Anticipated claims are invalid as a matter of law. The prior art must be prior to the claimed filing date (subject to first-to-file and the one-year grace period).
Strategy tip
Search for a single reference that teaches all elements of the independent claim as written. Foreign patents, journal articles, product manuals, and archived websites all qualify as prior art.
Ground 02
Obviousness
§ 103
Very common
The claimed invention would have been obvious to a person having ordinary skill in the relevant field (PHOSITA) at the time of filing. Unlike anticipation, multiple prior art references can be combined. The KSR International Co. v. Teleflex Inc. (2007) Supreme Court decision significantly broadened obviousness analysis, allowing flexible combinations of references based on market incentives, common sense, and predictable results.
Strategy tip
Find two or more prior art references that together teach all claim elements, and articulate a clear reason why a skilled person would combine them. Secondary considerations (long-felt need, commercial success, failure of others) can rebut obviousness.
Ground 03
Patent-ineligible subject matter
§ 101
Software/biotech
The claimed invention covers an abstract idea, law of nature, or natural phenomenon (the Alice/Mayo framework). Under Alice Corp. v. CLS Bank International (2014), a two-step analysis applies: (1) is the claim directed to an abstract idea? (2) If yes, does it add 'something more' that transforms it into patent-eligible subject matter? Software, diagnostic methods, and business method patents are most vulnerable to § 101 challenges.
Strategy tip
§101 challenges are evaluated claim-by-claim and can be raised in IPR (post-AIA) only at the PTAB via a motion to amend, but most effectively raised in district court litigation.
Ground 04
Lack of enablement or written description
§ 112
Biotech/pharma
The specification does not adequately enable a person of ordinary skill to make and use the full scope of the claimed invention (enablement), or the specification does not demonstrate that the inventor possessed the full scope of the claimed invention at the time of filing (written description). Broad genus claims in biotech where only a few species are exemplified in the specification are particularly vulnerable. The Supreme Court's Amgen Inc. v. Sanofi (2023) decision significantly tightened enablement for functional claim limitations.
Strategy tip
Particularly effective for extremely broad functional claims where the specification discloses only a few examples. The claim scope must be commensurate with the disclosure.
Ground 05
Inequitable conduct
Judicially created
Defense of last resort
The applicant deliberately withheld material information from the USPTO with specific intent to deceive, rendering the patent unenforceable (not invalid). After Therasense (Fed. Cir. 2011), courts require both but-for materiality and specific deceptive intent — mere negligence or gross negligence is not sufficient. When proven, it renders all claims in the patent (and sometimes related patents) permanently unenforceable.
Strategy tip
Look for material prior art the applicant cited against its own related applications but not in the application at issue, or prior art that contradicts statements made in the prosecution history.
Ground 06
Double patenting
OTDP / § 101 type
Portfolio attack
A patent applicant cannot receive two patents for the same invention (statutory double patenting, 35 U.S.C. § 101 type) or for obvious variations of each other (obviousness-type double patenting, OTDP). OTDP is the more common challenge — the claims of two related patents cannot be patentably distinct. OTDP can be overcome by filing a terminal disclaimer (limiting the patent's term to expire concurrently with the reference patent) and is therefore not always fatal.
Strategy tip
Relevant when a patent holder has continuation families — look for overlapping claim scope across related patents. Terminal disclaimers link patent terms together and can create vulnerabilities.
Challenge venues
Three places to challenge a patent
Where you challenge a patent matters enormously for cost, speed, available grounds, and strategic impact. The three venues are not mutually exclusive — many defendants pursue IPR and district court simultaneously.
District Court Litigation
Cost
$2M–$10M+
Timeline
2–5 years
Grounds: All grounds (§ 101, 102, 103, 112, inequitable conduct, double patenting)
Standard: Clear and convincing evidence
Pros
All invalidity grounds available. Jury trial option. Can get damages and injunction resolved simultaneously.
Cons
Expensive, slow. Requires patent holder to sue first (or declaratory judgment action).
Inter Partes Review (IPR)
Cost
$50,000–$200,000
Timeline
12–18 months
Grounds: § 102 and § 103 only — using prior art patents and printed publications
Standard: Preponderance of evidence
Pros
Lower burden of proof. Much cheaper than litigation. PTAB reversal rate is high (~75% of instituted trials find at least one claim unpatentable).
Cons
Limited to §102/§103 grounds and prior art only. Estoppel: IPR petitioner cannot later raise the same prior art in district court. Must be filed within 1 year of service of complaint.
Ex Parte Reexamination
Cost
$10,000–$50,000
Timeline
2–4 years
Grounds: § 102 and § 103 using prior art only
Standard: Preponderance of evidence
Pros
Anyone can request (anonymous submission possible). Relatively low cost.
Cons
Requestor has no participation rights after the request is filed. Lower PTAB reversal rate than IPR. Slower than IPR.
Strategy
Common invalidity strategies for defendants
IPR first, litigation second
File an IPR petition within one year of service of the infringement complaint. If instituted, district court often stays the litigation pending PTAB outcome. A PTAB win eliminates the patent at lower cost; even a partial win narrows the claims the plaintiff can assert.
Claim construction as validity tool
A narrow claim construction (Markman hearing) can simultaneously narrow the infringement case and expose the patent to prior art that doesn't read on the broader construction the plaintiff wants. This is why Markman strategy is often coordinated with invalidity analysis.
Prior user rights (§ 273)
Under the AIA, a party who commercially used a claimed process or machine in the US more than 1 year before the effective filing date of the patent has a complete defense to infringement — even if the patent is valid. This is distinct from invalidity: the patent is valid, but you had prior use rights.
Finding prosecution history estoppel vulnerabilities
Narrow amendments made during prosecution limit the patent holder's ability to claim equivalents. If the patent holder amended claims to overcome prior art during prosecution, the surrendered subject matter cannot be recaptured under the doctrine of equivalents — narrowing both infringement and the effective scope of validity.
FAQ
Common questions about patent invalidity
What is the burden of proof to invalidate a patent?
In district court litigation, a defendant must prove invalidity by 'clear and convincing evidence' — a higher standard than the 'preponderance of the evidence' (more likely than not) standard used in most civil cases. The Supreme Court confirmed this in Microsoft Corp. v. i4i Ltd. Partnership (2011). At the PTAB in inter partes review (IPR), the standard is 'preponderance of the evidence' — meaning IPR is easier than district court invalidity. This asymmetry is one reason defendants often file IPR concurrently with or before litigation.
What is the difference between invalidity and unenforceability?
Invalidity means the patent should never have been granted — the invention lacked novelty, was obvious, or was ineligible. Unenforceability is a separate defense — the patent exists but the owner cannot enforce it due to inequitable conduct (fraud on the patent office), patent misuse, or laches (unreasonable delay in bringing suit). Both are complete defenses to infringement. A patent can be valid but unenforceable, or both invalid and unenforceable.
Can a patent be partially invalidated?
Yes. Individual claims can be invalidated without affecting other claims in the same patent. A patent with 20 claims might have claims 1-5 invalidated at trial while claims 6-20 remain valid and enforceable. This is why broad independent claims are often the primary targets in invalidity challenges — invalidating an independent claim also eliminates all of its dependent claims. Patent holders sometimes maintain dependent claims specifically as fallback positions in litigation.
What is inter partes review (IPR) and how does it differ from litigation invalidity?
Inter partes review (IPR) is an administrative trial before the Patent Trial and Appeal Board (PTAB) at the USPTO, available for challenging granted patents on §102 (anticipation) and §103 (obviousness) grounds using prior art patents and printed publications only. Unlike district court litigation, IPR uses the preponderance of evidence standard, costs far less ($50,000–$200,000 vs $2M+ for litigation), and takes approximately 12–18 months. PTAB instituted IPR in about 56% of petitions and found at least one claim unpatentable in roughly 75% of completed trials in 2023. The trade-off: IPR petitioners are estopped from later raising the same prior art in district court.
What is inequitable conduct as a defense?
Inequitable conduct (also called fraud on the patent office) is a defense that renders a patent unenforceable — not invalid, but incapable of being enforced — when the applicant deliberately withheld material information from the USPTO with intent to deceive. The Federal Circuit significantly tightened this doctrine in Therasense, Inc. v. Becton, Dickinson and Co. (2011), requiring proof of both specific intent to deceive (not merely negligence) and but-for materiality (the omitted information would have prevented allowance). Inequitable conduct is therefore a high bar to prove but a powerful defense when it succeeds, because it can render all claims unenforceable.